Market Blog » The Arora Report Stock Market News

GOOGLE JELLY BEAN MAY CREAM AMAZON KINDLE, LITTLE THREAT TO APPLE

June 28, 2012

Google has a tradition of naming its operating systems after desserts. Jelly Bean is an incremental upgrade to Android Ice Cream Sandwich. The biggest improvement in Jelly Bean is in its search function and now presents information in a fashion similar to Apple Siri. Google has also introduced Nexus 7, a Google branded tablet. Steve Jobs called Android a stolen product, as he believed Android was copied from Apple (AAPL) iOS. If Steve Jobs was alive today, he would be aghast at Google copying another feature from Apple. Specifications of Nexus 7 come nowhere close to iPad. Nexus 7 has 1280 x 800 display

MORE ON THC

June 28, 2012

This post was just published on ZYX BuyChange Alert THC is a hospital chain. Under Obama Care hospitals are prime beneficiaries as they will start receiving payments from more patients who are now indigent. Some hospitals do not collect as much as 30% of their billing. Moreover, THC is an acquisition candidate. Those who acted quickly should have had fills before the halt. Those who acted after the halt should also have fills. Those still contemplating, we do not recommend buying higher than $5.30 preferably closer to $5.10. This will be a long-term position with a target of $11 to $13.

SUPREME COURT UPHOLDS OBAMA CARE

June 28, 2012

This post was just published on ZYX BuyChange Alert Supreme Court upheld Obama Care. Those who were fast should have fills on THC. Stock is halted.

BUY THC AGGRESSIVELY

June 28, 2012

This post was just published on ZYX BuyChange Alert Consider buying THC right here at $5.10.

MORE GUIDANCE ON ETP

June 28, 2012

This post was just published on ZYX BuyChange Alert Suggested buy points are $41, 41.26, $41.63, 42.11, $42.52, $42.75 and $43 18. Aggressive investors may also consider scaling in higher upto the upper band of the buy zone.

NEW IDEA ON ETP

June 28, 2012

This post was just published on ZYX BuyChange Alert ETP is a natural gas MLP and has a dividend of 8.1%. Those who have been interested in a high dividend paid MLP there is an opportunity, the stock has dipped below the secondary price. The buy zone is $41 to $43.82, target zone is $50 to $55. No stops at this time. Please be sure to follow Trade Management Guidelines.

ARENA OBESITY DRUG APPROVAL MAY SIGNAL FDA OPENING UP FAT PILL FLOODGATES

June 27, 2012

The U.S. Food and Drug Administration (FDA) has approved the first obesity drug in 15 years. The drug is lorcaserin, dubbed Belviq, from Arena Pharmaceuticals (ARNA). The drug works by affecting the area of the brain that regulates metabolism. The issue with weight loss drugs has not been efficacy, rather the side effects. The drug from Arena works similarly to Fen-phen. Fen-phen was banned about 15 years ago in the aftermath of serious side effects related to heart valves. The drug will be marketed by a Japanese company,Eisai. Projections are that lorcaserin will become a $1.5 billion drug. Jack Lief,

NEW IDEA ON OREXIGEN THERAPUTICS (OREX)

June 27, 2012

This post was published earlier on ZYX BuyChange Alert OREX is a sympathy play with ARNA. FDA has just approved ARNA weight loss drug. The risk is very high and this trade is only for aggressive investors. Buy zone is $3.90 -4.61. Stop zone is 3.43-3.73. Target zone is $6-7.50. This is a highly speculative position, please be sure to follow the Trade Management Guidelines. Only aggressive investors may chase the stock higher than the top band of the buy zone.